Last reviewed · How we verify
ACEI/CCB
This combination drug blocks both angiotensin-converting enzyme (ACE) and calcium channels to reduce blood pressure through dual vasodilation and reduced vasoconstriction.
This combination therapy simultaneously blocks angiotensin II formation (via ACE inhibition) and calcium channels to reduce blood pressure through complementary vasodilatory pathways. Used for Hypertension.
At a glance
| Generic name | ACEI/CCB |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Antihypertensive combination (ACEI/CCB) |
| Target | Angiotensin-converting enzyme; L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Calcium channel blockers prevent calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive antihypertensive effects with potentially improved tolerability compared to monotherapy.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
- Peripheral edema
- Hypotension
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- The GUARDIAN Pilot Trial (NA)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |